| Item |
Medicine |
| Brand name |
Sovaldi |
| Generic name |
Sofosbuvir |
| Final report date |
03/07/2018 |
|
|
| Target population (1) |
Chronic hepatitis C GT2(IFN-naive) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Less than JPY 5 million/QALY |
|
|
| Target population (2) |
Chronic hepatitis C GT2(IFN-experienced) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Less than JPY 5 million/QALY |
|
|
| Target population (3) |
Compensated cirrhosis C GT2(IFN-naive) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Less than JPY 5 million/QALY |
|
|
| Target population (4) |
Compensated cirrhosis C GT2(IFN-experienced) |
| Comparator |
Only follow-up (no treatment) |
| ICER |
Less than JPY 5 million/QALY |